Oxford BioMedica, Mayo Clinic enter research collaboration
As per the agreement, Mayo Clinic and Oxford BioMedica will take up clinical studies on glaucoma treatment using Oxford BioMedica’s LentiVector gene delivery technology. The technology expresses a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.